These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27030594)

  • 1. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
    Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
    Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
    Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
    Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
    Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
    Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive phenotypic and genomic characterization of venous malformations.
    Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
    Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A xenograft model for venous malformation.
    Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
    Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous malformations: PIK3CA mutations guide new treatments.
    Dbouk HA
    Oncotarget; 2016 Aug; 7(31):48852-48853. PubMed ID: 27447853
    [No Abstract]   [Full Text] [Related]  

  • 8. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
    Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
    Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component.
    Jauhiainen S; Ilmonen H; Vuola P; Rasinkangas H; Pulkkinen HH; Keränen S; Kiema M; Liikkanen JJ; Laham-Karam N; Laidinen S; Beter M; Aavik E; Lappalainen K; Lohi J; Aronniemi J; Örd T; Kaikkonen MU; Salminen P; Tukiainen E; Ylä-Herttuala S; Laakkonen JP
    Elife; 2023 May; 12():. PubMed ID: 37199488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
    Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
    EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for capillary-venous malformations.
    Zerbib L; Ladraa S; Fraissenon A; Bayard C; Firpion M; Venot Q; Protic S; Hoguin C; Thomas A; Fraitag S; Duong JP; Kaltenbach S; Balducci E; Lefevre C; Villarese P; Asnafi V; Broissand C; Goudin N; Nemazanyy I; Autret G; Tavitian B; Legendre C; Arzouk N; Minard-Colin V; Chopinet C; Dussiot M; Adams DM; Mirault T; Guibaud L; Isenring P; Canaud G
    Signal Transduct Target Ther; 2024 Jun; 9(1):146. PubMed ID: 38880808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic landscape of common venous malformations in the head and neck.
    Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
    J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial hyperactivation of mutant MAP3K3 induces cerebral cavernous malformation enhanced by PIK3CA GOF mutation.
    Huo R; Yang Y; Sun Y; Zhou Q; Zhao S; Mo Z; Xu H; Wang J; Weng J; Jiao Y; Zhang J; He Q; Wang S; Zhao J; Wang J; Cao Y
    Angiogenesis; 2023 May; 26(2):295-312. PubMed ID: 36719480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Patient-Derived Xenograft Model for Venous Malformation.
    Schrenk S; Goines J; Boscolo E
    J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations in vascular malformations.
    Castillo SD; Baselga E; Graupera M
    Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shear stress and pathophysiological PI3K involvement in vascular malformations.
    Abdelilah-Seyfried S; Ola R
    J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
    Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
    Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
    Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
    Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and Emerging Targeted Therapies for Vascular Malformations.
    Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
    Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
    Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.